Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14632793 | 0.83 | TSHR (0.50) | ENPP3ALPLXIAPTSHRF12 | |
| SCHEMBL2480409 | 0.82 | FAAH (0.38) | FAAHNR1H2HSP90AA1HSP90AB1MAP2K4 | |
| SCHEMBL2961171 | 0.81 | FAAH (0.40) | FAAHMAP2K4ELANESMARCA2SMARCA4 | |
| SCHEMBL4978183 | 0.81 | FAAH (0.37) | FAAHNR1H2HSP90AA1HSP90AB1MAP2K4 | |
| SCHEMBL939622 | 0.80 | FAAH (0.39) | FAAHNR1H2MAP2K4ELANEBCHE | |
| SCHEMBL5400751 | 0.80 | FAAH (0.39) | FAAHNR1H2MAP2K4ELANEBCHE | |
| SCHEMBL13024386 | 0.80 | FAAH (0.39) | FAAHMAP2K4ELANEBCHETSHR | |
| SCHEMBL25519570 | 0.80 | MAP2K4 (0.40) | FAAHNR1H2HSP90AA1HSP90AB1MAP2K4 | |
| SCHEMBL25519814 | 0.80 | FAAH (0.39) | FAAHNR1H2HSP90AA1HSP90AB1MAP2K4 | |
| SCHEMBL18284944 | 0.80 | FAAH (0.39) | FAAHNR1H2HSP90AA1HSP90AB1MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072541-B | Preparation method of targeted drug BLU-667 | 山东四环药业股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-113072541-A | Preparation method of targeted drug BLU-667 | 山东四环药业股份有限公司 | 2021-07-06 | — | — | CN | claimed |
| US-12358931-B2 | 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-12351582-B2 | Aurora kinase inhibitors and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2025-07-08 | — | — | US | disclosed |
| EP-4001276-B1 | AURORA KINASE INHIBITOR AND USE THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2025-06-25 | — | — | EP | disclosed |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| CN-116003441-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-116134022-B | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-115925705-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240417386-A1 | INHIBITORS OF RET | MIDCAP FINANCIAL TRUST | 2024-12-19 | — | — | US | disclosed |
| WO-2024230647-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2024-11-14 | — | — | WO | disclosed |
| US-7226923-B2 | Phthalazinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2007017649-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1718624-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| US-20060089359-A1 | Phthalazinone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | disclosed |
| WO-2006032518-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358931-B2 | 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor | JAK1, JAK3, JAK2 | FAAH 3889/4885NR1H2 4675/4885ENPP3 1475/4885 |
| US-20060089359-A1 | Phthalazinone derivatives | SDHA, SDHB, CYP3A5 | FAAH 4387/4885NR1H2 254/4885ENPP3 1182/4885 |
| US-20240417386-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | FAAH 4828/4885NR1H2 3571/4885ENPP3 2949/4885 |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | FAAH 4453/4885NR1H2 2350/4885ENPP3 1209/4885 |
| US-12351582-B2 | Aurora kinase inhibitors and uses thereof | AURKA, AURKC, AURKB | FAAH 4140/4885NR1H2 3349/4885ENPP3 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.